I watched this presentation the day after. The Q&A session was...

I watched this presentation the day after. The Q&A session was very enlightening and addressed the perceived potential issues around patients receiving multiple eye injections as well as the safety profile of the drug and all this by very experienced clinicians at the coal face seeing considerable numbers of patients on a daily basis. You tend to pick up tidbits from these sorts of presentations. One of the factors cited for the drawn out timeframes for these trials was the robustness of patient selection criteria.
I came away with the impression the company had progressed considerably along the pathway to commercialisation since the appointment of the new CE and his appointment had been a factor in the recent high calibre appointments to the company. The panel clearly knew each other well and it came across a bit like an old boys network. Having said that I would have to think why would guys of this calibre come on board unless they thought Opthea’s phase III trials had a high chance of success.